GB1535977A - Intravenous native human immunoglobulin with natural half-life period - Google Patents

Intravenous native human immunoglobulin with natural half-life period

Info

Publication number
GB1535977A
GB1535977A GB21047/76A GB2104776A GB1535977A GB 1535977 A GB1535977 A GB 1535977A GB 21047/76 A GB21047/76 A GB 21047/76A GB 2104776 A GB2104776 A GB 2104776A GB 1535977 A GB1535977 A GB 1535977A
Authority
GB
United Kingdom
Prior art keywords
serum
human immunoglobulin
intravenous
native human
natural half
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB21047/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotest Serum Institut GmbH
Original Assignee
Biotest Serum Institut GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Serum Institut GmbH filed Critical Biotest Serum Institut GmbH
Publication of GB1535977A publication Critical patent/GB1535977A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB21047/76A 1975-06-18 1976-05-21 Intravenous native human immunoglobulin with natural half-life period Expired GB1535977A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2527064A DE2527064C3 (de) 1975-06-18 1975-06-18 Verfahren zur Herstellung eines intravenösen Nativ-Human-Immunglobulin-Präparates mit natürlicher Halbwertszeit und gegenüber dem Ausgangsmaterial unveränderten Antikörperaktivität

Publications (1)

Publication Number Publication Date
GB1535977A true GB1535977A (en) 1978-12-13

Family

ID=5949318

Family Applications (1)

Application Number Title Priority Date Filing Date
GB21047/76A Expired GB1535977A (en) 1975-06-18 1976-05-21 Intravenous native human immunoglobulin with natural half-life period

Country Status (11)

Country Link
US (1) US4082734A (enExample)
JP (1) JPS521013A (enExample)
AT (1) AT356265B (enExample)
BE (1) BE841950A (enExample)
CA (1) CA1053153A (enExample)
CH (1) CH628518A5 (enExample)
DE (1) DE2527064C3 (enExample)
FR (1) FR2314730A1 (enExample)
GB (1) GB1535977A (enExample)
NL (1) NL7606581A (enExample)
SE (1) SE7606968L (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK139056B (da) * 1976-04-06 1978-12-11 Nordisk Insulinlab Fremgangsmåde til udvinding af immunoglobulin, der er egnet til intravenøs indgivelse.
US4164495A (en) * 1976-04-06 1979-08-14 Nordisk Insulinlaboratorium Method of recovering immunoglobulin using a polyol and an alkanoic acid
DE2658334C3 (de) * 1976-12-23 1987-05-07 Behringwerke Ag, 3550 Marburg Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel
US4374763A (en) * 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
ATE19735T1 (de) * 1982-02-08 1986-05-15 Schweiz Serum & Impfinst Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung.
DE3310150A1 (de) * 1983-03-21 1984-09-27 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer nebenwirkungsfreien igg-immunglobulinloesung fuer die intravenoese applikation
DE3344656A1 (de) * 1983-12-09 1985-06-13 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung einer serumproteinloesung
CH662824A5 (de) * 1984-02-14 1987-10-30 Graf & Co Ag Kardiersegment.
AU6948787A (en) * 1986-03-10 1987-09-28 Rubinstein, A.I. A method for treating gammaglobulin
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3927111C3 (de) * 1989-08-17 1994-09-01 Biotest Pharma Gmbh Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
US5256771A (en) * 1990-04-03 1993-10-26 Miles Inc. Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
BE1012448A3 (fr) * 1998-12-07 2000-11-07 S C R L Dept Central De Fracti Standard utilise dans des tests de diagnostic et/ou de quantification.
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1198277A (en) 1967-09-05 1970-07-08 Ustav Ser A Ockovacich Latek O Process for the Preparation of Serum Gamma Globulins by Fractionation of Blood Serum, Plasma or Raw Serum Fractions with Quaternary Ammonium Compounds
DE1792555C3 (de) 1968-09-19 1980-01-10 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung einer für die intravenöse Anwendung geeigneten Gammaglobulinlösung
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
CA1007568A (en) * 1973-12-13 1977-03-29 Michael C. Attwell Bovine immunoglobulin isolation process

Also Published As

Publication number Publication date
CA1053153A (en) 1979-04-24
JPS5516488B2 (enExample) 1980-05-02
CH628518A5 (de) 1982-03-15
FR2314730A1 (fr) 1977-01-14
FR2314730B1 (enExample) 1978-12-15
DE2527064C3 (de) 1979-11-15
NL7606581A (nl) 1976-12-21
SE7606968L (sv) 1976-12-19
AT356265B (de) 1980-04-25
JPS521013A (en) 1977-01-06
DE2527064B2 (de) 1979-03-29
BE841950A (fr) 1976-09-16
ATA395576A (de) 1979-09-15
DE2527064A1 (de) 1976-12-23
US4082734A (en) 1978-04-04

Similar Documents

Publication Publication Date Title
GB1535977A (en) Intravenous native human immunoglobulin with natural half-life period
Reynolds et al. Inhibition of B lymphocyte activation by interferon-gamma.
Takatsu et al. Purification and physicochemical characterization of murine T cell replacing factor (TRF).
NZ185846A (en) Gamma globulin fractions substantially free of anticomplementary acitivity pharmaceutical compositions for intravenous administration
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
ES8601983A1 (es) Procedimiento para preparar derivados de tiazol
Bazin et al. Differential effect of neonatal injections of Anti-µ or Anti-δ antibodies on the synthesis of IgM, IgD, IgE, IgA, IgG1, IgG2a, IgG2b, and IgG2c immunoglobulin classes
IE820815L (en) Anti-cancer drug.
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
PT78019B (en) Process for preparing rebeccamycin and of pharmaceutical compositions containing the same
GB1505513A (en) Dental caries inhibiting product
Ma et al. Association of transport-defective light chains with immunoglobulin heavy chain binding protein
GB1420411A (en) Pyridine compounds and process for their manufacture
Hanna et al. Inhibition of T-and B-lymphocyte functions by normal immunosuppressive protein
Wood et al. Receptor sites for antigen-antibody complexes on cells derived from solid tumors: Detection by means of antibody sensitized sheep erythrocytes labeled with technetium-99m
GB1528259A (en) Process for the preparation of a gamma-globulin solution suitable for intravenous administration
Chiao et al. Suppression of lymphocyte activation and functions by a leukemia cell-derived inhibitor.
DE3164719D1 (en) Drugs with cytostatic activity, derivatives of isocyanuric acid and process for their preparation
Masuoka et al. Conversion of C14-Arterenol to Epinephrine in vivo.
MY107386A (en) Method of preventing or reducing eosinophilia
Stutman et al. H–2 restriction and non-restriction of T-cell-mediated cytotoxicity against mouse mammary tumour targets
GB1399824A (en) Heparin esters
GB1514049A (en) Cross-linked orgotein
Salama et al. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia
GB1526996A (en) Substituted sulphoximides a process for their preparation and pharmaceutical compositions containing these compound

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19930521